Reaching very low LDL levels with a PCSK9 inhibitor was not associated with any increase in neurocognitive adverse events, according to the largest and most rigorous study to assess the topic to date.Small and preliminary studies have raised concerns over the possibility of the neurocognitive effects of statins. Though most clinicians and scientists have not ...
Ebbinghaus study may help refute doctor google
By Larry Husten
20 Mar 2017